Yao Jiasu (Yao Acceleration) hat angekündigt, dass es eine Angel-Runde von mehreren Millionen Yuan erfolgreich abgeschlossen hat. Light Source Capital fungiert als exklusiver Finanzberater.
Hangzhou Yaojiasu Medical Isotope Technology Co., Ltd. (hereinafter referred to as "Yaojiasu"), a hard - tech enterprise dedicated to breaking through the supply bottleneck of GMP - grade medical isotopes, officially announced today that it has completed an angel - round financing of tens of millions of RMB. This round of financing was jointly participated in by the Innovation Institute of Zhejiang University, Bangming Capital, and the industrial partner Wuzhou Medical. Light Source Capital served as the exclusive financial advisor. The financing funds will be mainly used for expanding the core team, advancing technological R & D, and promoting the commercialization process of key products such as the α - nuclide Ac - 225.
Nuclides, also known as radioactive isotopes, show unique advantages in disease diagnosis and treatment due to their precise radioactive properties and have broad clinical application prospects. Among many medical nuclides, α - nuclides are regarded as an important direction for the next - generation nuclear medicine treatment because of their excellent targeted killing ability, high safety, and low toxic and side effects. Taking Ac - 225 (actinium - 225) as an example, it has a moderate half - life, which facilitates production, transportation, and stable binding with targeting molecules. In the field of tumor treatment, Ac - 225 shows outstanding application potential, especially having an excellent targeted killing effect on widely metastasized micro - lesions.
Yaojiasu is committed to breaking through the supply bottleneck of medical isotopes and aims to build a high - performance, high - efficiency, and replicable domestic nuclide technology engineering system. The company is building an integrated platform of "high - energy and high - current electron accelerator + high - power target station system + GMP - grade separation and purification process" around the medical radioactive isotope production technology driven by electron accelerators to promote the large - scale preparation and engineering implementation of actinides and diagnosis - treatment integrated nuclides. Based on the independently designed high - power electron linear accelerator system, the company has constructed a precision target station with high - power load capacity, a rapid heat - exchange structure, and a short - range and efficient cooling path. Coupled with a multi - stage separation and purification process, it can achieve stable production and strict quality control of key nuclides such as Ac - 225, Cu - 67, Sc - 47, and Mo - 99. The whole system supports rapid target replacement, remote maintenance, and modular expansion, suitable for continuous operation scenarios, laying a solid hardware foundation for the large - scale mass production of nuclides such as Ac - 225.
Yaojiasu's R & D team brings together experts in the fields of accelerator physics, electro - vacuum, and nuclear chemical separation from institutions such as the Chinese Academy of Sciences, the University of Science and Technology of China, and Harbin Institute of Technology. They have the full - chain technical capabilities from accelerator design and manufacturing, optimization of nuclear reaction paths to process scaling - up and industrialization of nuclide separation.
After completing this round of financing, Yaojiasu will further accelerate the construction of its production lines and technological iteration, promote the commercial production and delivery of core nuclides such as Ac - 225, and help the Chinese nuclear medicine diagnosis and treatment industry achieve high - quality independent development.
Gu Shengdong, co - founder and CEO of Yaojiasu, said: "We are very grateful for the support of all shareholders and Light Source Capital, which gives us more strength to do things well. The nuclear medicine industry is developing rapidly, and medical isotopes are crucial for cancer diagnosis and treatment. Yaojiasu has solid technological accumulation and team capabilities. We will go all out to accelerate R & D and industrialization, ensure stable production as soon as possible, and bring truly useful results to patients."
The Innovation Institute of Zhejiang University said: "The excellent clinical data of innovative nuclear medicines have brought explosive growth to the entire nuclear medicine industry. Among them, nuclide production is a crucial part of the entire industrial chain. The Yaojiasu team has rich experience in accelerator manufacturing, debugging, and nuclide separation and purification. They produce innovative nuclides through high - current electron accelerators to solve the current global shortage of nuclides. We look forward to the company's early completion of the commercial production of nuclides to benefit a large number of patients."
Bangming Capital said: "Bangming has always adhered to the concepts of 'long - termism' and 'value discovery and creation'. We are very optimistic about the development prospects of α - nuclide radioactive drugs in the field of tumor treatment. The Yaojiasu team has years of technological accumulation in accelerator design and manufacturing, optimization of nuclear reaction paths, process scaling - up and industrialization of nuclide separation. Their independently developed high - energy and high - current electron accelerator is expected to complete the commercial mass production of α - nuclides, solving the dual bottlenecks of technology and production capacity that China has long relied on imports for. Bangming is honored to participate in a science and technology innovation enterprise with growth potential like Yaojiasu and is willing to continuously support the enterprise's rapid development and jointly build the cause of science and technology innovation."
Wuzhou Medical said: "Although Ac - 225 performs outstandingly in clinical applications, its production process is complex, and the global supply is extremely limited, seriously restricting clinical applications. Yaojiasu can overcome the core technology of mass - producing Ac - 225, which is expected to solve the supply shortage problem of Ac - 225. This is not only a major breakthrough in the nuclear medicine industry but also brings hope to a large number of cancer patients."
Hong Lei, the person - in - charge of the medical department and managing director of Light Source Capital, said: "Currently, the global nuclear medicine industry is in a period of vigorous development, and its clinical value has been widely recognized. The innovation and breakthrough in this field highly depend on the stable supply of isotopes, which are the underlying foundation. The production of isotopes, especially new nuclides such as Ac - 225, has become a key restrictive factor for the industry's development. For a long time, China has highly relied on imports for high - value new nuclides, restricting the independent development of the industry. With its integrated technology platform, Yaojiasu directly addresses the pain points of the'supply - chain bottleneck' and is expected to break this pattern of external dependence. We are very optimistic about the company's technological path and team execution ability. In the future, Light Source will continue to provide in - depth capital and strategic support to help the company seize historical opportunities and grow into a core force leading the development of the Chinese medical nuclide industry."
About the Innovation Institute of Zhejiang University
The Innovation Technology Research Institute Co., Ltd. of Zhejiang University is jointly established by the holding group of Zhejiang University on behalf of Zhejiang University, the State - owned Assets Supervision and Administration Commission of Zhejiang Province, state - owned enterprises in Zhejiang Province and Hangzhou, as well as many well - known listed companies, private industrial leaders, and financial investment groups. The company has long been engaged in the transformation, incubation, and industrialization of scientific and technological achievements, is committed to the transformation, incubation, and investment operation of scientific and technological innovation projects, cultivates the ecological environment for emerging industries, and provides new - quality services for regional economic construction and development.
About Bangming Capital
Bangming Capital was established in 2010. It is a professional venture capital institution that has long adhered to the concept of value investment and invests in "technology + entrepreneurship" - type enterprises. Currently, it is the vice - president unit of the Shanghai Venture Capital Industry Association. Since its establishment, Bangming Capital has always focused on key technologies and scientific and technological innovations in three major fields: integrated circuits and the new - generation electronic information, innovative medical biology, and new materials and new energy. Adhering to the spirit of "long - termism" and the concept of value discovery/value creation, we insist on growing together with the most promising science and technology innovation enterprises and entrepreneurs in China and jointly building the cause of science and technology innovation.
About Wuzhou Medical
Hangzhou Wuzhou Medical Equipment Co., Ltd. was established on January 22, 2003. At the beginning of its establishment, the company established the mission of promoting early diagnosis and treatment and making life better. It is committed to providing early diagnosis and treatment products for thousands of customers and early diagnosis and treatment services for hundreds of millions of people. Currently, the company has four branches across the country, and its services cover medical institutions in four regions: Zhejiang, Shanxi, Gansu, and Tianjin, promoting related projects such as the nuclear - Hai De Wei breath test, the Hunan Youli prostate small extracellular protein (PSEP) detection kit, and the early - risk screening for diabetes by the Chinese Academy of Sciences.